Skip to main content
Publications
Vogel A, Qin S, Kudo M, Su Y, Hudgens S, Yamashita T, Yoon JH, Fartoux L, Simon K, Lopez C, Sung M, Mody K, Ohtsuka T, Tamai T, Bennett L, Meier G, Breder V. Lenvatinib versus sorafenib for first-line treatment of unresectable hepatocellular carcinoma: patient-reported outcomes from a randomised, open-label, non-inferiority, phase 3 trial. Lancet Gastroenterol Hepatol. 2021 Aug;6(8):649-58. doi: 10.1016/S2468-1253(21)00110-2
Gilbertson DT, Rothman KJ, Chertow GM, Bradbury BD, Brookhart MA, Liu L, Winkelmayer WC, Sturmer T, Monda KL, Herzog CA, Ashfaq A, Collins AJ, Wetmore JB. Excess deaths attributable to influenza-like illness in the ESRD population. J Am Soc Nephrol. 2019 Feb;30(2):346-53. doi: 10.1681/ASN.2018060581
Chertow GM, Liu J, Monda KL, Gilbertson DT, Brookhart MA, Beaubrun AC, Winkelmayer WC, Pollock A, Herzog CA, Ashfaq A, Sturmer T, Rothman KJ, Bradbury BD, Collins AJ. Epoetin alfa and outcomes in dialysis amid regulatory and payment reform. J Am Soc Nephrol. 2016 Oct;27(10):3129-38. doi: 10.1681/ASN.2015111232
Pavel M, Horsch D, Anthony L, Ervin C, Kulke MH, Bergsland E, Caplin M, Oberg K, Warner R, Kunz P, Metz DC, Pasieka J, Pavlakis N, DiBenedetti D, Lapuerta P. Patient interviews in TELESTAR, a phase 3 study of telotristat etiprate, report meaningful improvement in carcinoid syndrome. Poster presented at the 2016 European Neuroendocrine Tumor Society (ENETS) Annual Meeting; March 2016. Barcelona, Spain. [abstract] Neuroendocrinology. 2016; 103:89.